Evaluation of CNS-Active Drugs for Worldwide Submission
In this complimentary webinar, Dr. Beatrice Setnik and Dr. Andy Mead take a comprehensive look at the key differences between the EMA and FDA drug development requirements when evaluating CNS-active drugs for abuse potential, as well as the need for a controlled substance designation.
Questions? Speak with our scientists.
You may also be interested in the following:
- Podcast: Altasciences' Scientific Experts Discuss Safety Pharmacology
- Webinar: Navigating Early Phase CNS-Active Drug Development
- Fact Sheet: Driving Simulation Studies
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.